Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 22:18:1143-1155.
doi: 10.2147/TCRM.S351300. eCollection 2022.

Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)

Affiliations
Review

Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)

Fabiano de Oliveira Poswar et al. Ther Clin Risk Manag. .

Abstract

Mucopolysaccharidosis VII (MPS VII, Sly syndrome) is an ultra-rare lysosomal disease caused by a deficiency of the enzyme β-glucuronidase (GUS). The diagnosis is suspected based on a range of symptoms that are common to many other MPS types, and it is confirmed through biochemical and molecular studies. Besides supportive treatment, current and emerging treatments include enzyme replacement therapy, hematopoietic stem cell transplantation, and gene therapy. This review summarizes the clinical manifestations, diagnosis, and emerging treatments for MPS VII.

Keywords: Sly syndrome; enzyme replacement therapy; gene therapy; hematopoietic stem cell transplantation; lysosomal disorders; mucopolysaccharidosis type VII.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest related to this work.

Figures

Figure 1
Figure 1
Clinical manifestations of MPS VII. Clinical photographs show coarse facial features, with a short neck and abnormal dentition (A), as well as joint contractures with claw hands (B), and genu valgum (C). Radiographic signs of dysostosis multiplex include broad ribs, hip dysplasia and scoliosis (D); thoracolumbar gibbus (E); odontoid dysplasia (F). Informed consent was obtained for the publication of patient images.
Figure 2
Figure 2
Therapeutic approaches for MPS VII. Enzyme replacement therapy leads to significant improvement in patient’s quality of life, with disease correction in many visceral tissues; however, it is costly, requires the support of health centers, and there is the possibility of immune reactions. Hematopoietic stem cell transplantation, on the other hand, is effective in the brain, though it must be performed early in life, it takes time for cells to fully engraft and be effective, a matching donor is necessary, and there is always a life-threatening risk of graft rejection or graft-versus-host disease. Finally, gene therapy should be a once-in-a-lifetime treatment (or a few times throughout the lifespan of the patient), able to target the central nervous system specifically and improve cognition significantly, although it can be a very invasive procedure with associated risks inherent to viral vectors.

Similar articles

Cited by

References

    1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Michell GA, editors. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw Hill; 2007.
    1. Verheyen S, Blatterer J, Speicher MR, et al. Novel subtype of mucopolysaccharidosis caused by arylsulfatase K (ARSK) deficiency. J Med Genet. 2021;jmedgenet-2021–108061. doi:10.1136/JMEDGENET-2021-108061 - DOI - PMC - PubMed
    1. Wiesinger AM, Bigger B, Giugliani R, et al. The inflammation in the cytopathology of patients with mucopolysaccharidoses- immunomodulatory drugs as an approach to therapy. Front Pharmacol. 2022;1797. doi:10.3389/FPHAR.2022.863667 - DOI - PMC - PubMed
    1. Vianey-Saban C, Acquaviva C, Cheillan D, et al. Antenatal manifestations of inborn errors of metabolism: biological diagnosis. J Inherit Metab Dis. 2016;39(5):611–624. doi:10.1007/s10545-016-9947-8 - DOI - PubMed
    1. Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005;94(7):872–877. doi:10.1080/08035250510031584 - DOI - PubMed